Spectracef

(cefditoren pivoxil)

ApprovedSmall molecule

Alnylam Pharmaceuticals

Spectracef is one of 102 small molecule programs targeting Sinusitis. It is currently in Approved.

Indications

Total Trials

Active Trials

101

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

SinusitisActive, not recruiting

PneumoniaActive, not recruiting

CystitisActive, not recruiting

SinusitisApproved

Active, not recruiting

PneumoniaApproved

Active, not recruiting

CystitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Spectracef

Alnylam Pharmaceuticals

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Acanya

Pfizer

Preclinical

1 4

Prevacid

Takeda

Preclinical

1 5

Avlosulfon

AAlmirall, S.A.

Preclinical

4 6

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

2 7

Zantac 150

CChattem

Preclinical

2 8

Retrovir

BBp Consulting, Inc

Preclinical

2 9

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 10

Mycifradin

PPharmacia and Upjohn

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sinusitis1 trial

Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis

Unknown status·TThammasat University·Phase 4·NCT01553006·120 enrolled

Cystitis1 trial

Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis

Completed·TTedec-Meiji Farma, S.A.·Phase 3·NCT00598403·611 enrolled

Breast1 trial

Pharmacokinetic Study of Cefditoren Pivoxil in Breast Milk and Blood of Lactating Women

Completed·WWest China Second University Hospital·N/A·NCT06644105·12 enrolled

Pneumonia1 trial

Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia

Completed·MMeiji Pharma Spain S.A.·Phase 4·NCT04709172·20 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 29, 2001

SPECTRACEF

NDA NDA021222

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for cefditoren pivoxil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cefditoren pivoxil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cefditoren pivoxil. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021222). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Alnylam Pharmaceuticals

Spectracef

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sinusitis1 trial

Cystitis1 trial

Breast1 trial

Pneumonia1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News